Table 5 Characteristics of adjuvant therapy
TDT group (n = 33) | CMS group (n = 26) | |
|---|---|---|
Adjuvant therapy | ||
Stage II | ||
Negative | 7 | 6 |
Oral 5FU/leucovorin or oral 5FU | 3 | 2 |
Capecitabine + oxaliplatin | 0 | 3 |
mFOLFOX6 | 1 | 0 |
Stage III | ||
Negative | 2 | 2 |
Oral 5FU/leucovorin or oral 5FU | 7 | 1 |
Capecitabine + oxaliplatin ∓ bevacizumab | 1 | 2 |
unknown | 1 | 1 |
Stage IV | ||
Best supportive care | 3 | 2 |
Oral 5FU/leucovorin or oral 5FU | 1 | 2 |
mFOLFOX6 ∓ bevacizumab | 3 | 2 |
mFOLFOX6 + panitumumab | 0 | 1 |
Capecitabine + oxaliplatin ∓ bevacizumab | 1 | 2 |
S1 + oxaliplatin + bevacizumab | 1 | 0 |
Others | 2 | 0 |